Bromazolāms

Bromazolam is a synthetic triazolobenzodiazepine first synthesized in 1976 but never marketed for medical use. It emerged as a designer drug, first definitively identified in Sweden by the EMCDDA in 2016. Structurally, it is the bromo analogue of alprazolam and produces comparable sedative and anxiolytic effects at a similar potency. As with other benzodiazepines, bromazolam carries significant habit-forming potential and poses risks of dependence with repeated use.

Also known as: Brom, Bromaz, Xli-268

Classification

Chemical: Benzodiazepine
Psychoactive: Depressant
Tag: Anxiolytic
Tag: GABAergic
Tag: Habit-Forming
Tag: Muscle Relaxant
Tag: Research-Chemical
Tag: Tentative

Effects

Physical Fatigue
Increased Heart Rate
Seizure
Sedation
Muscle Relaxation
Anxiety Suppression
Amnesia
Thought Deceleration
Analysis Suppression
Confusion
Delirium
Auditory Hallucination
External Hallucination
Acuity Suppression
Dulled Perception
Disinhibition

Routes of Administration

Oral

Dosage

Heavy: 4 mg
Light: 0.5 – 1 mg
Common: 1 – 2 mg
Strong: 2 – 4 mg
Threshold: 0.5 mg

Duration

Onset: 0.25-0.75 h
After Effects: 1-12 h

Harm Reduction

Check interactions before mixing substances, pay attention to dose spacing and hydration, and treat all dosage guidance as approximate rather than guaranteed safe.

Sources

Substance data is aggregated from the following public harm-reduction and reference sources.

Links

This static page is intended as a readable non-JS and prerender-friendly library export.

Get the full DrugsPRO experience

Open the interactive DrugsPRO app for search, saved items, interactions, and deeper harm reduction tools.

Get the PRO test kit. The simple, quick and reliable drug checking test kit. Visit https://protestkit.eu